PENTAPEPTIDE-18

Skin, Hair & CosmeticCosmetic

Extremely limited research base with just one small human study and no randomized trials. The cosmetic industry uses it widely, but scientific validation lags far behind commercial adoption.

Primarily researched by cosmetic companies developing premium anti-aging serums and creams, often as part of peptide cocktails rather than standalone formulations.

FDA Status

Research Only

Since Feb 2026

Evidence

Limited data

Studies

4 total, 1 human

What is PENTAPEPTIDE-18?

Originally developed as Leuphasyl, this five-amino-acid sequence has carved out a niche in anti-aging skincare formulations where cosmetic chemists prize its ability to target expression lines. The peptide functions as a topical muscle relaxant, designed to complement more established cosmetic peptides like Argireline in multi-ingredient anti-wrinkle products.

The peptide works by hijacking the body's natural pain-relief system, specifically mimicking enkephalins that normally bind to opioid receptors in nerve endings. When applied topically, it essentially tricks facial nerve terminals into reducing their calcium uptake, which in turn dampens the release of neurotransmitters that trigger muscle contractions underlying crow's feet and forehead lines.

What the Research Shows

Research consists of just 4 studies total, with only a single non-randomized human trial and the remainder focusing on formulation stability rather than efficacy.

Based on 4 total studies (1 human study, 0 RCTs), pentapeptide-18 showed stability in retinol formulations over 4-week storage and demonstrated reduced melanin synthesis in cell and tissue models, though clinical efficacy evidence is limited to a single non-randomized human study reporting improvements in sebum secretion and facial wrinkles with enhanced tolerability when combined with retinol in nanocarrier systems.